2019-03-12 Comments Off on Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain February 19, 2019 — Pfizer Inc. (NYSE: PFE) and Eli
